Table 2 Baseline characteristics with number of patients
From: Rigor prophylaxis in stage IV melanoma and renal cell carcinoma patients treated with high dose IL-2
Meperidinea (N = 42) | Tramadolb (N = 49) | ||||
|---|---|---|---|---|---|
N pts | % | N pts | % | p-value | |
Race | 0.177 | ||||
White | 43 | 88% | 36 | 86% | |
Hispanic | 3 | 6% | 4 | 10% | |
American Indian | 3 | 6% | 0 | 0% | |
Unknown | 0 | 0% | 2 | 5% | |
Gender | 0.232 | ||||
Female | 14 | 29% | 17 | 40% | |
Male | 35 | 71% | 25 | 60% | |
Previous treatment | 17 | 35% | 7 | 17% | 0.052 |
Malignancy | 0.088 | ||||
Renal Cell Carcinoma | 39 | 80% | 26 | 63% | |
Melanoma | 10 | 20% | 15 | 37% | |
Tramadol | 10 | 24% | 49 | 100% | < 0.001 |